Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals S.p.A.    NWRN   IT0004147952

NEWRON PHARMACEUTICALS S.P.A.

(NWRN)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
05/18/2020 05/19/2020 05/20/2020 05/22/2020 05/25/2020 Date
1.798(c) 1.8(c) 1.76(c) 1.81(c) 1.844 Last
110 555 161 260 77 790 69 493 41 881 Volume
-4.16% +0.11% -2.22% +2.84% +1.88% Change
More quotes
Financials
Sales 2020 6,05 M 6,59 M 6,59 M
Net income 2020 -27,2 M -29,6 M -29,6 M
Net Debt 2020 5,81 M 6,33 M 6,33 M
P/E ratio 2020 -1,12x
Yield 2020 -
Sales 2021 62,5 M 68,1 M 68,1 M
Net income 2021 12,4 M 13,5 M 13,5 M
Net cash position 2021 0,22 M 0,24 M 0,24 M
P/E ratio 2021 2,49x
Yield 2021 -
Capitalization 30,5 M 33,2 M 33,2 M
EV / Sales 2020 6,01x
EV / Sales 2021 0,48x
Nbr of Employees 26
Free-Float 94,1%
More Financials
Company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron... 
More about the company
Latest news on NEWRON PHARMACEUTICALS S.P
05/07NEWRON PHARMACEUTICALS S.P.A. : Notification and public disclosure of transactio..
EQ
05/04NEWRON PHARMACEUTICALS S P A : Reports Top-Line Results from its STARS Study Eva..
EQ
05/04Newron Reports Top-Line Results from its STARS Study Evaluating Sarizotan in ..
TE
04/30SUPERNUS PHARMACEUTICALS : Newron Acknowledges Definitive Agreement between US W..
AQ
04/16NEWRON PHARMACEUTICALS S P A : Receives Third Tranche from Financing Agreement w..
AQ
04/15NEWRON PHARMACEUTICALS S P A : Receives Third Tranche from Financing Agreement w..
EQ
04/15NEWRON PHARMACEUTICALS S P A : Receives Third Tranche from Financing Agreement w..
BU
03/31NEWRON PHARMACEUTICALS S P A : AGM Result and Clinical and Business Update
EQ
03/31NEWRON PHARMACEUTICALS S P A : AGM Result and Clinical and Business Update
BU
03/11NEWRON PHARMACEUTICALS S P A : updates on STARS study FDA interaction
EQ
03/11Newron updates on STARS study FDA interaction
TE
03/05NEWRON PHARMACEUTICALS S P A : announces 2019 financial results and provides out..
EQ
03/05Newron announces 2019 financial results and provides outlook for 2020
TE
02/17NEWRON PHARMACEUTICALS S P A : Expands Global Rett Syndrome Burden of Illness Su..
BU
02/17NEWRON PHARMACEUTICALS S P A : Expands Global Rett Syndrome Burden of Illness Su..
EQ
More news
News in other languages on NEWRON PHARMACEUTICALS S.P
05/07NEWRON PHARMACEUTICALS S.P.A. : Meldung und öffentliche Bekanntgabe der Geschäft..
05/07Newron Pharmaceuticals S.p.A.
05/05Un déconfinement à tout prix
05/05AVIS D'ANALYSTES DU JOUR : Capgemini, Dufry, Electrolux, Eurofins, Kering, Nestl..
05/04NEWRON : échec d'une étude clinique sur le sarizotan contre le syndrome de Rett
More news
Chart NEWRON PHARMACEUTICALS S.P
Duration : Period :
Newron Pharmaceuticals S.p Technical Analysis Chart | NWRN | IT0004147952 | MarketScreener
Technical analysis trends NEWRON PHARMACEUTICALS S.P
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 38,00 €
Last Close Price 1,71 €
Spread / Highest target 2 124%
Spread / Average Target 2 124%
Spread / Lowest Target 2 124%
EPS Revisions
Managers
NameTitle
Stefan Weber Chief Executive Officer, Director & IR Contact
Ulrich Köstlin Non-Executive Chairman
Roberto Galli Vice President-Finance
Ravi Anand Chief Medical Officer
Luca Benatti Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS S.P.A.-71.50%33
GILEAD SCIENCES12.87%91 996
VERTEX PHARMACEUTICALS30.15%73 883
REGENERON PHARMACEUTICALS51.78%63 465
WUXI APPTEC CO., LTD.16.15%24 438
GENMAB A/S36.89%19 339